Physiologic colonic uptake of
18F-FDG colonic uptake
Gut microbiome
Immunotherapy
Metagenomics
Non-small cell lung cancer
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
15
08
2020
accepted:
15
10
2020
pubmed:
1
11
2020
medline:
29
5
2021
entrez:
31
10
2020
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICI) represent the backbone treatment for advanced non-small cell lung cancer (NSCLC). Emerging data suggest that increased gut microbiome diversity is associated with favorable response to ICI and that antibiotic-induced dysbiosis is associated with deleterious outcomes. Seventy-one patients with advanced NSCLC who underwent a PET/CT prior to ICI were identified. Blinded colonic contouring was performed for each colon segment and patients were stratified according to the median of the average colon SUV The high colon SUV Lower colon physiologic
Sections du résumé
BACKGROUND
Immune checkpoint inhibitors (ICI) represent the backbone treatment for advanced non-small cell lung cancer (NSCLC). Emerging data suggest that increased gut microbiome diversity is associated with favorable response to ICI and that antibiotic-induced dysbiosis is associated with deleterious outcomes.
METHODS
Seventy-one patients with advanced NSCLC who underwent a PET/CT prior to ICI were identified. Blinded colonic contouring was performed for each colon segment and patients were stratified according to the median of the average colon SUV
RESULTS
The high colon SUV
CONCLUSIONS
Lower colon physiologic
Identifiants
pubmed: 33128571
doi: 10.1007/s00259-020-05081-6
pii: 10.1007/s00259-020-05081-6
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1550-1559Références
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35:3924–33. https://doi.org/10.1200/JCO.2017.74.3062 .
doi: 10.1200/JCO.2017.74.3062
pubmed: 29023213
pmcid: 6075826
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–39. https://doi.org/10.1056/NEJMoa1507643 .
doi: 10.1056/NEJMoa1507643
pubmed: 26412456
pmcid: 5705936
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373:123–35. https://doi.org/10.1056/NEJMoa1504627 .
doi: 10.1056/NEJMoa1504627
pubmed: 26028407
pmcid: 4681400
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–65. https://doi.org/10.1016/s0140-6736(16)32517-x .
doi: 10.1016/s0140-6736(16)32517-x
Antonia SJ, Borghaei H, Ramalingam SS, Horn L, De Castro CJ, Pluzanski A, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019;20:1395–408. https://doi.org/10.1016/s1470-2045(19)30407-3 .
doi: 10.1016/s1470-2045(19)30407-3
pubmed: 31422028
pmcid: 7193685
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33. https://doi.org/10.1056/NEJMoa1606774 .
doi: 10.1056/NEJMoa1606774
pubmed: 27718847
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040–51. https://doi.org/10.1056/NEJMoa1810865 .
doi: 10.1056/NEJMoa1810865
pubmed: 30280635
Elkrief A, Joubert P, Florescu M, Tehfe M, Blais N, Routy B. Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020. Curr Oncol. 2020;27:52–60. https://doi.org/10.3747/co.27.5953 .
doi: 10.3747/co.27.5953
pubmed: 32218661
pmcid: 7096203
Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50. https://doi.org/10.1016/s0140-6736(15)01281-7 .
doi: 10.1016/s0140-6736(15)01281-7
pubmed: 26712084
Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in non–small cell lung cancer: facts and hopes. Clin Cancer Res. 2019;25:4592–602. https://doi.org/10.1158/1078-0432.ccr-18-1538 .
doi: 10.1158/1078-0432.ccr-18-1538
pubmed: 30824587
pmcid: 6679805
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301. https://doi.org/10.1056/NEJMoa1716948 .
doi: 10.1056/NEJMoa1716948
pubmed: 29863955
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348:124–8. https://doi.org/10.1126/science.aaa1348 .
doi: 10.1126/science.aaa1348
pubmed: 25765070
pmcid: 4993154
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–7. https://doi.org/10.1126/science.aan3706 .
doi: 10.1126/science.aan3706
pubmed: 29097494
Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368–79. https://doi.org/10.1093/annonc/mdx108 .
doi: 10.1093/annonc/mdx108
pubmed: 28368458
Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97–103. https://doi.org/10.1126/science.aan4236 .
doi: 10.1126/science.aan4236
pubmed: 29097493
Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104–8. https://doi.org/10.1126/science.aao3290 .
doi: 10.1126/science.aao3290
pubmed: 29302014
pmcid: 6707353
Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen Y, et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol. 2019;14:1378–89. https://doi.org/10.1016/j.jtho.2019.04.007 .
doi: 10.1016/j.jtho.2019.04.007
pubmed: 31026576
Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncol. 2019;30:1572–9. https://doi.org/10.1093/annonc/mdz206 .
doi: 10.1093/annonc/mdz206
pubmed: 31268133
Wilson BE, Routy B, Nagrial A, Chin VT. The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Cancer Immunol Immunother. 2020;69:343–54. https://doi.org/10.1007/s00262-019-02453-2 .
doi: 10.1007/s00262-019-02453-2
pubmed: 31865400
Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, et al. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. Oncoimmunology. 2019;8:e1568812. https://doi.org/10.1080/2162402X.2019.1568812 .
doi: 10.1080/2162402X.2019.1568812
pubmed: 30906663
pmcid: 6422373
Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5:1774–8. https://doi.org/10.1001/jamaoncol.2019.2785 .
doi: 10.1001/jamaoncol.2019.2785
pubmed: 31513236
pmcid: 6743060
Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur Urol. 2020;78:195–206. https://doi.org/10.1016/j.eururo.2020.04.044 .
doi: 10.1016/j.eururo.2020.04.044
pubmed: 32376136
Hakozaki T, Richard C, Elkrief A, Hosomi Y, Benlaïfaoui M, Mimpen I, et al. The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non–small cell lung cancer. Cancer Immunol Res. 2020; 8:1243–1250. https://doi.org/10.1158/2326-6066.CIR-20-0196 .
Utzschneider KM, Kratz M, Damman CJ, Hullar M. Mechanisms linking the gut microbiome and glucose metabolism. J Clin Endocrinol Metab. 2016;101:1445–54. https://doi.org/10.1210/jc.2015-4251 .
doi: 10.1210/jc.2015-4251
pubmed: 26938201
pmcid: 4880177
Boursi B, Werner TJ, Gholami S, Houshmand S, Mamtani R, Lewis JD, et al. Functional imaging of the interaction between gut microbiota and the human host: a proof-of-concept clinical study evaluating novel use for 18F-FDG PET-CT. PLoS One. 2018;13:e0192747. https://doi.org/10.1371/journal.pone.0192747 .
doi: 10.1371/journal.pone.0192747
pubmed: 29447210
pmcid: 5813966
Bybel B, Brunken RC, DiFilippo FP, Neumann DR, Wu G, Cerqueira MD. SPECT/CT imaging: clinical utility of an emerging technology. Radiographics. 2008;28:1097–113. https://doi.org/10.1148/rg.284075203 .
doi: 10.1148/rg.284075203
pubmed: 18635631
Dore J, Ehrlich SD, Levenez F, Pelletier E, Alberti A, Bertrand L and IHMS Consortium (2015). IHMS_SOP 05 V1: Standard operating procedure forfecal samples preserved in stabilizing solution self‐collection, laboratory analysis handled within 24 hours to 7 days (24 hours ˂ x ≤ 7 days). International Human Microbiome Standards. 2015. http://www.microbiome-standards.org . Accessed March 5th, 2020.
Suau A, Bonnet R, Sutren M, Godon J-J, Gibson GR, Collins MD, et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol. 1999;65:4799–807.
doi: 10.1128/AEM.65.11.4799-4807.1999
Visconti A, Martin TC, Falchi M. YAMP: a containerized workflow enabling reproducibility in metagenomics research. Gigascience. 2018;7:1–9. https://doi.org/10.1093/gigascience/giy072 .
Segata N, Waldron L, Ballarini A, Narasimhan V, Jousson O, Huttenhower C. Metagenomic microbial community profiling using unique clade-specific marker genes. Nat Methods. 2012;9:811–4. https://doi.org/10.1038/nmeth.2066 .
doi: 10.1038/nmeth.2066
pubmed: 22688413
pmcid: 3443552
McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One. 2013;8:e61217. https://doi.org/10.1371/journal.pone.0061217 .
doi: 10.1371/journal.pone.0061217
pubmed: 23630581
pmcid: 3632530
Bray JR, Curtis TJ. An ordination of upland forest communities of southern Wisconsin. Ecol Monogr. 1957;27:325–49. https://doi.org/10.2307/1942268 .
doi: 10.2307/1942268
Zhu C, Yu J. Nonmetric multidimensional scaling corrects for population structure in association mapping with different sample types. Genetics. 2009;182:875–88. https://doi.org/10.1534/genetics.108.098863 .
doi: 10.1534/genetics.108.098863
pubmed: 19414565
pmcid: 2710166
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https://doi.org/10.1186/s13059-014-0550-8 .
doi: 10.1186/s13059-014-0550-8
pubmed: 25516281
pmcid: 25516281
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026 .
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
pmcid: 19097774
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81. https://doi.org/10.1080/01621459.1958.10501452 .
doi: 10.1080/01621459.1958.10501452
Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–70.
pubmed: 5910392
Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220–30. https://doi.org/10.1038/nature11550 .
doi: 10.1038/nature11550
pubmed: 22972295
pmcid: 3577372
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–31. https://doi.org/10.1038/nature05414 .
doi: 10.1038/nature05414
pubmed: 17183312
Blander JM, Longman RS, Iliev ID, Sonnenberg GF, Artis D. Regulation of inflammation by microbiota interactions with the host. Nat Immunol. 2017;18:851–60. https://doi.org/10.1038/ni.3780 .
doi: 10.1038/ni.3780
pubmed: 28722709
pmcid: 5800875
Boursi B, Werner TJ, Gholami S, Margalit O, Baruch E, Markel G, et al. Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma. Melanoma Res. 2019;29:318–21. https://doi.org/10.1097/cmr.0000000000000566 .
doi: 10.1097/cmr.0000000000000566
pubmed: 30557217
Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–84. https://doi.org/10.1126/science.aad1329 .
doi: 10.1126/science.aad1329
pubmed: 26541610
pmcid: 4721659
Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019;7:193. https://doi.org/10.1186/s40425-019-0650-9 .
doi: 10.1186/s40425-019-0650-9
pubmed: 31337439
pmcid: 6651993